Table 3.

Toxicity

	Every-3-weeks platinum	Weekly platinum	P-value	Every-3-weeks cisplatinum	Weekly carboplatinum	P-value
	(N = 144)	(N = 68)		(N = 138)	(N = 52)
Median total hospital days	3	0	.03	3	0	.08
(IQR)	(0–9)	(0–4)		(0–9)	(0–4)
Hospitalizations			.04			.04
Yes	62 (43.1%)	28 (41.2%)		60 (43.5%)	21 (40.4%)
No	49 (34.0%)	33 (48.5%)		46 (33.3%)	26 (50.0%)
Not stated	33 (22.9%)	7 (10.3%)		32 (23.2%)	5 (9.6%)
Feeding tube during RT			.11			.09
Yes	72 (50.0%)	26 (38.2%)		67 (48.6%)	18 (34.6%)
No	72 (50.0%)	42 (61.8%)		71 (51.5%)	34 (65.4%)
Weight loss >10%			.17			.06
Yes	72 (50.0%)	30 (44.1%)		71 (51.4%)	23 (44.2%)
No	36 (25.0%)	24 (35.3%)		33 (23.9%)	21 (40.4%)
Not stated	36 (25.0%)	14 (20.6%)		34 (24.6%)	8 (15.4%)
Grade ≥ 3 mucositis			.47			.25
Yes	35 (24.3%)	19 (27.9%)		33 (23.9%)	17 (32.7%)
No	85 (59.0%)	36 (52.9%)		83 (60.1%)	28 (53.8%)
Not stated	24 (16.7%)	13 (19.1%)		22 (15.9%)	7 (13.5%)
Grade ≥ 3 dermatitis			.54			.70
Yes	6 (4.2%)	4 (5.9%)		6 (4.3%)	3 (5.8%)
No	115 (79.9%)	51 (75.0%)		111 (80.4%)	42 (80.8%)
Not stated	23 (16.0%)	13 (19.1%)		21 (15.2%)	7 (13.5%)
Feeding tube at last follow-up			.46			.15
Yes	43 (29.9%)	17 (25.0%)		41 (29.7%)	10 (19.2%)
No	101 (70.1%)	51 (75.0%)		97 (70.3%)	42 (80.8%)
Tracheotomy at last follow-up			.67			.21
Yes	20 (13.9%)	8 (11.8%)		20 (14.5%)	4 (7.7%)
No	124 (86.1%)	60 (88.2%)		118 (85.5%)	48 (92.3%)
AKI during RT			<.001			<.01
Yes	72 (50.0%)	15 (22.1%)		68 (49.3%)	15 (28.9%)
No	40 (27.8%)	40 (58.8%)		39 (28.3%)	29 (55.8%)
Not stated	32 (22.2%)	13 (19.1%)		31 (%)	8 (15.4%)

AKI acute kidney injury, IQR interquartile range, RT radiotherapy